{"title":"The efficacy of sorafenib after progression on atezolizumab and bevacizumab combination therapy in a patient with advanced hepatocellular carcinoma","authors":"Yun-Tzu Lin, Hung‐Chang Wu","doi":"10.4103/2311-3006.362637","DOIUrl":null,"url":null,"abstract":"Sorafenib was approved for the treatment of hepatocellular carcinoma more than 10 years ago; however, the efficacy is limited. The IMbrave150 trial demonstrated better overall survival and progression-free survival with atezolizumab plus bevacizumab combination therapy compared to sorafenib, and so it has become the choice of first-line treatment. However, the optimal choice of subsequent therapy after atezolizumab plus bevacizumab is unknown. We present a case with advanced hepatocellular carcinoma who achieved a complete response for more than 2 years under sorafenib treatment after progression with atezolizumab and bevacizumab combination therapy.","PeriodicalId":31219,"journal":{"name":"Journal of Cancer Research and Practice","volume":"9 1","pages":"149 - 152"},"PeriodicalIF":0.0000,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Research and Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/2311-3006.362637","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Sorafenib was approved for the treatment of hepatocellular carcinoma more than 10 years ago; however, the efficacy is limited. The IMbrave150 trial demonstrated better overall survival and progression-free survival with atezolizumab plus bevacizumab combination therapy compared to sorafenib, and so it has become the choice of first-line treatment. However, the optimal choice of subsequent therapy after atezolizumab plus bevacizumab is unknown. We present a case with advanced hepatocellular carcinoma who achieved a complete response for more than 2 years under sorafenib treatment after progression with atezolizumab and bevacizumab combination therapy.
期刊介绍：
JCRP aims to provide an exchange forum for the cancer researchers and practitioners to publish their timely findings in oncologic disciplines. The scope of the Journal covers basic, translational and clinical research, Cancer Biology, Cancer Immunotherapy, Hemato-oncology, Digestive cancer, Urinary tumor, Germ cell tumor, Breast cancer, Lung cancer, Head and Neck Cancer in a vast range of cancer related topics. The Journal also seeks to enhance and advance the cancer care standards in order to provide cancer patients the best care during the treatments.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
